Top

Published in:

01-02-2016 | Editorial

Note of clarification regarding data on the association between the interleukin-1β −511C>T polymorphism and breast cancer risk

Authors: Yadong Wang, Xinwei Chu, Haiyu Wang

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Excerpt

With great interest, we have read a recent article entitled “Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis”, which was published online in Breast Cancer Research and Treatment [1]. In this article, Liu et al. conducted a meta-analysis to address the association between the interleukin-1β (IL-1β) gene −511C>T polymorphism and the risk of breast cancer [1]. Their results showed that the polymorphism of IL-1β −511C>T was not associated with the risk of breast cancer. It is an extremely valuable study. …

Liu X, Wang Z, Yu J, Lei G, Wang S (2010) Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis. Breast Cancer Res Treat 124:821–825CrossRefPubMed

Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173CrossRefPubMed

Liu J, Zhai X, Jin G, Hu Z, Wang S, Wang X, Qin J, Gao J, Ma H, Wei Q et al (2006) Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. Int J Cancer 118:2554–2558CrossRefPubMed

Hefler LA et al (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res 11(16):5718–5721CrossRefPubMed

Balasubramanian SP et al (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6(1):188PubMedCentralCrossRefPubMed

Pooja S et al (2012) Polymorphic variations in IL-1β, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. Cytokine 60(1):122–128CrossRefPubMed

Title: Note of clarification regarding data on the association between the interleukin-1β −511C>T polymorphism and breast cancer risk
Authors: Yadong Wang
Xinwei Chu
Haiyu Wang
Publication date: 01-02-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3722-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2016

HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline

Erratum to: A nomogram based on mammary ductoscopic indicators for evaluating the risk of breast cancer in intraductal neoplasms with nipple discharge

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer

Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice

Comparison of intra-operative specimen mammography to standard specimen mammography for excision of non-palpable breast lesions: a randomized trial

The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer